Catalent, Inc. (NYSE:CTLT) CEO Sells $87,230.40 in Stock

Catalent, Inc. (NYSE:CTLT – Get Rating) CEO Alessandro Maselli sold 816 shares of Catalent stock in a transaction dated Tuesday, July 26th. The shares were sold at an average price of $106.90, for a total value of $87,230.40. Following the sale, the chief executive officer now owns 25,083 shares of the company’s stock, valued at approximately $2,681,372.70. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Catalent Price Performance

Shares of Catalent stock opened at $113.10 on Friday. The company has a debt-to-equity ratio of 0.90, a current ratio of 2.89 and a quick ratio of 2.25. The business’s 50 day simple moving average is $106.25 and its two-hundred day simple moving average is $102.89. The stock has a market capitalization of $20.27 billion, a P/E ratio of 40.98, a price-to-earnings-growth ratio of 1.64 and a beta of 1.32. Catalent, Inc. has a one year low of $86.34 and a one year high of $142.64.

Catalent (NYSE:CTLT – Get Rating) last announced its quarterly earnings results on Tuesday, May 3rd. The company reported $1.00 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.11. The business had revenue of $1.27 billion for the quarter, compared to analysts’ expectations of $1.22 billion. Catalent had a return on equity of 15.07% and a net margin of 10.72%. The business’s quarterly revenue was up 20.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.78 EPS. Analysts forecast that Catalent, Inc. will post 3.57 EPS for the current year.

Hedge Funds Weigh In On Catalent

A number of large investors have recently bought and sold shares of the stock. Cerro Pacific Wealth Advisors LLC increased its stake in Catalent by 2.4% in the 1st quarter. Cerro Pacific Wealth Advisors LLC now owns 4,575 shares of the company’s stock worth $507,000 after purchasing an additional 107 shares during the period. Manchester Capital Management LLC increased its stake in Catalent by 13.3% in the 4th quarter. Manchester Capital Management LLC now owns 980 shares of the company’s stock worth $125,000 after purchasing an additional 115 shares during the period. Ellevest Inc. increased its stake in Catalent by 39.5% in the 1st quarter. Ellevest Inc. now owns 406 shares of the company’s stock worth $45,000 after purchasing an additional 115 shares during the period. Kestra Advisory Services LLC increased its stake in shares of Catalent by 6.2% during the fourth quarter. Kestra Advisory Services LLC now owns 2,129 shares of the company’s stock valued at $273,000 after buying an additional 125 shares during the period. Finally, C M Bidwell & Associates Ltd. increased its stake in shares of Catalent by 5.7% during the fourth quarter. C M Bidwell & Associates Ltd. now owns 2,355 shares of the company’s stock valued at $302,000 after buying an additional 127 shares during the period. 98.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Deutsche Bank Aktiengesellschaft dropped their target price on Catalent from $129.00 to $110.00 and set a “hold” rating for the company in a research report on Tuesday, April 12th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $142.86.

About Catalent

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services.